BIM (FITC)

BIM (FITC) (CPC catalog code CANC-001) is a synthetic oncology research peptide in the oncology category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use BIM (FITC) as a reference standard in oncology workflows — for example, receptor-targeted drug-delivery research and apoptosis and cell-viability assays. Human clinical evidence is not established.

No. BIM (FITC) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a oncology workflow, BIM (FITC) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. MTT / CellTiter-Glo viability, caspase-3/7 activation, and receptor-binding SPR.

Store lyophilized at −20 °C. Aliquot reconstituted stocks to minimize freeze–thaw damage. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for CANC-001. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.